Abstract
Development of novel patient stratification tools for cancer is a challenge that require advanced molecular screening and a detailed understanding of tumour signalling networks. Here, we apply phospho-specific flow cytometry for signal profiling of primary glioblastoma tumours after preservation of single-cell phosphorylation status as a strategy for evaluation of tumour signalling potential and assessment of rapamycin-mediated mTOR inhibition. The method has already enhanced insight into cancers and disorders of the immune system, and our study demonstrate a great potential to improve the understanding of aberrant signalling in glioblastoma and other solid tumours.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibiotics, Antineoplastic / pharmacology*
-
Base Sequence
-
Brain Neoplasms / pathology*
-
Cell Proliferation / drug effects
-
Epidermal Growth Factor / metabolism*
-
Flow Cytometry
-
Gene Expression Regulation, Neoplastic / drug effects
-
Gene Expression Regulation, Neoplastic / genetics
-
Gene Library
-
Glioblastoma / pathology*
-
Humans
-
Phosphorylation / drug effects
-
Signal Transduction / drug effects*
-
Sirolimus / pharmacology*
-
TOR Serine-Threonine Kinases / metabolism*
-
Time Factors
-
Tumor Cells, Cultured
Substances
-
Antibiotics, Antineoplastic
-
Epidermal Growth Factor
-
MTOR protein, human
-
TOR Serine-Threonine Kinases
-
Sirolimus